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The Bcl-2 (B-cell lymphoma 2) antiapoptotic gene has been discovered in virtue of its over-expression occurring 
in B-cell leukemias/lymphomas carrying the 14;18 chromosomal translocation [t(14;18)], which places the Bcl-2 
gene next to the immunoglobulin heavy chain (IgH) locus. In this condition, the transcription of the Bcl-2 moiety 
of the Bcl-2/IgH fusion gene is driven by the four enhancers located in 3’ of the IgH moiety and is, therefore, 
excessive. This leads to overproduction of Bcl-2 protein, which confers a survival advantage that contributes to 
neoplastic transformation. Nevertheless, in most malignancies, comprising chronic lymphocytic leukemias, 
breast, prostate, colorectal and lung cancer, the over-expression of Bcl-2 does not imply chromosomal 
rearrangements, suggesting that alterations at post-transcriptional level could be involved. Collaborating with 
the group of Angelo Nicolin (University of Milan, Italy), we first disclosed the existence of a Bcl-2 
post-transcriptional control based on interplay among an Adenine and uracil-Rich cis-acting Element (ARE) 
located in the 3’UTR of Bcl-2 mRNA and several trans-acting ARE-Binding Proteins (AUBPs). We also 
demonstrated its deregulation in human leukemias/lymphomas. In particular, we have identified some Bcl-2 
AUBPs - such as AUF-1, TINO/hMex-3D, the Bcl-2 protein itself and ζ-Crystallin - and described their 
qualitative or quantitative alterations in cancer cells. Moreover, in the attempt to correct Bcl-2 deregulation in 
the human diseases characterized by defects or excesses of apoptosis, we have modulated exogenously Bcl-2 
expression by means of different antisense strategies. In this research highlight, we briefly report our 
proceedings, in which a long non-coding Bcl-2/IgH antisense RNA (Bcl-2/IgH AS) we discovered in a 
serendipitous manner has played a key role. 
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The key role of apoptosis defects consequent to 
overexpression of Bcl-2 (B-cell lymphoma 2) gene in cancer 
development and therapy has been widely recognized [1]. 
Bcl-2 has been discovered in B-cell leukemias/lymphomas 
carrying the 14;18 chromosomal translocation t(14;18), 
which places the Bcl-2 gene next to the immunoglobulin 
heavy chain (IgH) locus and is therefore over-transcribed by 
four enhancers located in 3’ of the IgH moiety. This leads to 
the production of excessive amounts of the Bcl-2 
antiapoptotic oncoprotein [2], responsible for a survival 
advantage leading to neoplastic transformation [3]. 
Nevertheless, in most malignancies, such as chronic 
lymphocytic leukemias, breast, prostate, colorectal and lung 
cancer, Bcl-2 over-expression can occur in the absence of 
chromosomal rearrangements, which suggests that it could be 
caused by alterations at post-transcriptional level. A large 
amount of evidences indicates that up- and down-regulation 
of Bcl-2 expression is modulated at transcriptional, 
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post-transcriptional, including mRNA stability and 
translational control, and post-translational levels. 
Expression of the Bcl-2 gene was known to be regulated 
transcriptionally by a negative regulatory element [4] and by 
two estrogen-responsive elements identified within its coding 
region in a breast cancer cell line [5]. An 11 amino-acidic 
upstream Open Reading Frame (uORF) located within the 
5’UTR of Bcl-2 mRNA inhibits translation of Bcl-2 protein 
[6]. In addition, Bcl-2 translation is controlled by the presence 
of an Internal Ribosome Entry Site (IRES) within the Bcl-2 
mRNA 5’UTR. Bcl-2 IRES activity is induced upon cell 
stress, when cap-dependent translation is repressed, and 
enables to replenish levels of Bcl-2 protein preventing 
unwarranted apoptosis induction [7]. A mechanism of 
post-translational control of Bcl-2 expression has been 
described to be mediated by phosphorylation of Bcl-2 protein 
at different amino acid positions [8, 9]. Two decades ago, 
starting from the serendipitous identification of a long non 
coding Bcl-2/IgH antisense RNA in t(14;18) leukemic cells, 
in collaboration with the group of Angelo Nicolin 
(University of Milan, Italy) we identified a complex 
post-transcriptional mechanism of Bcl-2 regulation, which 
proceedings are described below. 
Aimed to reduce Bcl-2 over-expression in t(14;18) cells 
carrying the Bcl-2/IgH fusion gene by antisense strategies we 
surprisingly noted that, whilst synthetic antisense 
oligodeoxyribonucleotides (aODNs) targeting Bcl-2 or IgH 
RNA did not elicit any effect, the relevant 
oligodeoxyribonucleotides designed in sense orientation 
(sODNs) as controls induced a marked decrease of Bcl-2 
mRNA and protein [10]. The ability of sODNs in 
down-regulating Bcl-2 expression suggested that bona fide 
they could target a natural Bcl-2/IgH antisense RNA that, 
since its inactivation by sODNs leaded to down-regulation of 
Bcl-2 expression, could overlap/mask a negative regulative 
element located in the hybrid Bcl-2/IgH mRNA. We obtained 
the direct evidence of the actual existence of a long 
non-coding antisense Bcl-2/IgH RNA (Bcl-2/IgH AS) by a 
strand-specific PCR analysis, followed by directly 
sequencing of PCR products. The Bcl-2/IgH AS was present 
in t(14;18) follicular lymphoma DOHH2 cells while was 
absent in untranslocated Burk1itt’s lymphoma Raji and 
Acute Lymphatic Leukemia (ALL) Jurkat cells, which 
indicated that its existence was conditioned by the t(14;18) 
translocation generating the Bcl-2/IgH hybrid oncogene 
(Figure 1). Originating in the IgH locus, encompassing the 
t(14;18) fusion site and spanning at least the complete 3’ 
UTR region of the Bcl-2 mRNA, the hybrid Bcl-2/IgH AS 
has a certain relationship with another antisense transcript 
previously identified in Burkitt lymphomas starting in the 
mu-switch region of the IgH locus and spanning the c-myc 
gene [11]. The study of the pathophysiological role of the long 
non-coding RNAs is one of the most intriguing aspects of 
post-transcriptional control of gene expression [12]. 
For many years, the fusion sequences arising from 
chromosomal translocations have been recognized highly 
tumor-specific molecular targets for ODNs [13, 14]. In analogy, 
the Bcl-2/IgH AS has proven an optimal target for synthetic 
Figure 1. Schematic structure of t(14;18) translocation juxtaposing the Bcl-2 gene to the IgH locus. (A) The 
hybrid Bcl-2/IgH gene showing UTRs of the Bcl-2 moiety (purple hatched) flanking the coding region (red hatched) 
and the IgH moiety (orange hatched). Intronic sequences are reported as lines. (B) The hybrid Bcl-2/IgH mRNA 
showing its ORF (red hatched) and its ARE (green hatched). (C) The hybrid Bcl-2/IgH antisense RNA showing the 
extension of the portion revealed (blue line) by the strand specific RT-PCR, which includes the ARE overlapping 
stretch. 
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ODNs, being of more general relevance respect to the single 
fusion points of each individual t(14;18) cell line we have 
tested [15]. Indeed, we have targeted the Bcl-2/IgH AS either 
within the Bcl-2/IgH fusion regions, which have a sequence 
specificity presumably limited to a single cell line, or within 
the ectopic Bcl-2 region upstream from the major breakpoint 
region and the IgH segment, which sequence specificity is 
extended to all cells carrying the t(14;18). Although all 
sODNs complementary to the Bcl-2/IgH AS induced a fast 
reduction of proliferation and a late but massive apoptosis, 
while the effectiveness of ODNs targeting the Bcl-2/IgH 
fusion regions was limited to each cell line, the effectiveness 
of all ODNs targeting the Bcl-2 or IgH regions was extended 
to all t(14;18) cell lines. The selectivity and efficacy of all 
sODNs tested provided support for the development of 
therapeutic ODNs targeting Bcl-2/IgH AS expressed in 
human follicular lymphomas. 
Searching for the negative regulative element we supposed 
to be harbored in the Bcl-2 mRNA moiety on Bcl-2/IgH 
RNA, we found that the 3' untranslated region (3’UTR) of 
Bcl-2 contained a 107-nucleotide Adenine+uracyl Rich 
Element (ARE) provided with a series of AUUUA repeats 
similar to others elements endowed with mRNA negative 
regulative functions [16]. Besides its impressive evolutionary 
conservation (from C. elegans to humans), the Bcl-2 ARE 
had all the features of a typical ARE, included a particular 
distribution of the AUUUA pentamers near an 
UUAUUUAUU nonamer, which let it ascribe to the class II 
AREs according to the classification proposed by Shyu et al. 
[17, 18]. The class II AREs usually impart a biphasic kinetic of 
degradation to their relevant mRNA, are sensitive to 
actinomycin D treatment, and do not necessarily act on 
translation. Bona fide, the Bcl-2/IgH AS could stabilize the 
Bcl-2 mRNA in t(14;18) cells by overlapping its ARE. 
AREs modulate the fate of relevant mRNAs (in terms of 
stability, localization and translation) by interacting with a 
series of trans-acting factors included RNA-binding proteins, 
namely ARE-binding proteins (AUBPs) and miRNAs. On 
this basis, the exhaustive clarification of the ARE dependent 
post-transcriptional control of Bcl-2 expression required 
identification and functional analysis of the Bcl-2 AUBPs. 
For this purpose, we firstly demonstrated in Jurkat cells that 
the ARE of Bcl-2 ARE bound to several cytoplasmic 
proteins, which molecular weights were from 35 to 100 kDa, 
and whose pattern underwent modifications in response to 
apoptotic stimuli. We hypothesized that these proteins must 
be trans-acting regulators in the ARE mediated degradation 
of Bcl-2 mRNA during apoptosis [19]. Considering the 
antiapoptotic activity of Bcl-2, our observations strongly 
suggested that possible alterations of Bcl-2 AUBPs could 
contribute to carcinogenesis and neoplastic progression.  
The first analyses of the Bcl-2 AUBPs in Bcl-2 
over-expressing cell lines demonstrated significant 
alterations with respect to the normal counterpart. In 
particular, the observation that proteins ranging from 30–50 
kDa underwent the most noticeable increase led us to 
hypothesize that AU-rich element RNA-binding protein 1 
(AUF1) could be a Bcl-2 ARE-binding protein. Indeed, 
AUF1, first identified as an RNA-binding protein with 
selective affinity for AREs located within mRNAs such as 
c-myc, c-fos, and GM-CSF [20, 21], is comprised of four 
isoforms of 37, 40, 42, and 45 kDa. We demonstrated that 
AUF1 bound to the Bcl-2 mRNA both in vitro and in vivo 
and that potentially all its isoforms constituted complexes 
with the Bcl-2 ARE in Jurkat cells [22]. At doses able to 
induce apoptosis, UVC irradiation induced an increase of 
cytoplasmic levels of the p45 AUF1 isoform, which 
paralleled an enhancement of a Bcl-2 mRNA/AUF1 complex 
and subtended a mechanism requiring caspase activation. 
These results indicated that ARE-mediated Bcl-2 mRNA 
down-regulation during apoptosis involved AUF1 and 
suggested different roles for its four isoforms. 
By using a non-radioactive cell-free mRNA decay system 
we observed that the degradation of Bcl-2 mRNA was related 
to the amount of Bcl-2 protein expressed by different cell 
types at steady state, was lost upon Bcl-2 depletion and was 
reconstituted by adding recombinant Bcl-2. This clearly 
indicated that Bcl-2 was necessary to activate the degradation 
complex on the relevant RNA target [23]. Successively, in the 
context of a AUBPs silencing approach, we demonstrated 
that Human antigen R (HuR) knockdown reduced the 
expression of endogenous Bcl-2, whereas increased 
significantly a Bcl-2 ARE-reporter transcript, which 
suggested that HuR expression has opposite effects on 
endogenous and ectopic Bcl-2 ARE [24]. Having also 
demonstrated that Bcl-2 protein had a specific and dose 
dependent role in regulating its own mRNA degradation and 
that its activity overcame the activity of HuR, we suggested 
that Bcl-2 was the main determinant of Bcl-2 mRNA 
turnover [24]. Confirming our observations, Ishimaru D. et al. 
demonstrated that HuR plays a positive role in Bcl-2 mRNA 
stability and translation regulation in HL60 leukemia and 
A431 epidermoid carcinoma cells [25]. We have also shown 
by UV cross-linking that KH-type splicing regulatory protein 
(KSRP) and Tristetraprolin (TTP) bound in vitro to the Bcl-2 
mRNA [26]. While the functional role of KSRP on Bcl-2 
remains to be disclosed, Park SB et al. have very recently 
demonstrated the ability of TTP to down-regulate Bcl-2 
expression in head and neck cancer cells in response to 
cisplatin [27]. 
In an attempt to search for other Bcl-2 mRNA binding 
proteins, we used the yeast RNA three-hybrid system assay 
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and identified a novel human protein we named TINO, which 
interacted with Bcl-2 ARE [28]. Upon binding, TINO had a 
post-transcriptional negative activity on Bcl-2 expression, 
demonstrated by its ability to destabilize a chimeric reporter 
construct containing the Bcl-2 ARE. The predicted sequence 
of TINO had two heterogeneous nuclear ribonucleoprotein K 
homology (KH) amino-terminal motifs for the nucleic acid 
binding and a carboxy-terminal RING domain endowed with 
a putative protein E3 ubiquitin ligase activity. In addition, 
using the protein-protein BLAST analysis, we observed that 
the novel protein was evolutionarily conserved. In particular, 
we identified Posterior End Mark-3 (PEM-3) of Ciona 
savignyi and Muscle EXcess protein-3 (MEX-3) of 
Caenorhabditis elegans as TINO orthologous proteins. More 
recently, TINO has been recognized as a variant form of 
hMex-3D [29]. Compared to hMex-3D, TINO is truncated in 
its N-terminal region, beginning at the first KH domain. This 
form of hMex-3D also differs at its C-terminal end, with 19 
amino acids, encoded by a potential alternative exon, 
replacing the four last terminal amino acids of hMex-3D. We 
did not succeed in identifying TINO protein in any 
experimental model and conditions we have explored. 
Although the function of TINO/hMex-3D remains to be 
clarified, some data reported in the literature combined with 
a series of our preliminary results strongly suggest that it 
could be involved in a conserved circuit comprising 
Quaking/GLD-1 and ζ-Crystallin, which alteration leads to 
stem cell polarity disruption and acquisition of cancer 
phenotype [30]. 
Five years ago, by means of a bidimensional SDS-PAGE 
carried out on bcl-2 AUBPs from phytoemoagglutinin 
(PHA)-activated T lymphocytes or Jurkat T-cells followed 
by mass spectrometry analysis, we have identified 
ζ-crystallin as a new Bcl-2 AUBP, which augmented binding 
to the Bcl-2 mRNA in ALL T-cells and increased Bcl-2 
expression by enhancing the stability of its mRNA [31]. The 
specific association of ζ-crystallin to the Bcl-2 ARE was 
significantly higher in T cells of ALL patients respect to 
normal T cells, which accounted for the higher stability of 
Bcl-2 mRNA and suggested a possible contribution of 
ζ-crystallin to Bcl-2 overexpression occurring in this 
leukemia. Surprisingly, we found that the cytoplasmic levels 
of ζ-crystallin did not differ in normal PHA-activated 
T-lymphocytes with respect to leukemia T-cells, indicating 
that the different binding of ζ-crystallin to the Bcl-2 ARE in 
leukemia T-cells did not depend on its concentration and 
might be explained by other mechanisms, which remain to be 
disclosed. We propose two alternative scenarios: the first 
predicts that qualitative alterations of the ζ-crystallin protein 
in ALL T-cells allow increased Bcl-2 ARE binding; the 
second proposes that modifications of Bcl-2 AUBPs pattern 
in ALL T-cells could advantage ζ-crystallin interaction with 
the Bcl-2 ARE. 
Others have identified further Bcl-2 AUBPs. They are 
Figure 2. Scheme of the Bcl-2 mRNA. The position and sequence of the Bcl-2 mRNA AU-Rich Element (ARE) and 
its stabilizing or destabilizing ARE-Binding proteins (AUBPs) are shown. References are listed in brackets. 
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Nucleolin, which overexpression and altered subcellular 
localization in Chronic Lymphatic Leukemia (CLLs) leads to 
excessive Bcl-2 mRNA stability [32]; EBP1, endowed with 
destabilizing activity on a chimeric construct harboring the 
Bcl-2 ARE in HL-60 leukemia cells [33]; ZFP36L1, which 
Bcl-2 mRNA destabilizing activity has been demonstrated in 
leukemia, lymphoma and renal carcinoma cell lines [34] 
(Figure 2). Furthermore, some miRNA have also been 
demonstrated to be involved in Bcl-2 post-transcriptional 
control and in its alterations in human leukemias [35-38]. Very 
recently, Díaz-Muñoz MD et al. have disclosed the ability of 
Bcl-2 AUBP/ARE association to stabilize in vivo Bcl-2 
mRNA, contributing to Bcl-2 protein over-production and B 
cell survival [39]. 
The complex of the past and current literature clearly 
indicate that the pathogenesis of most human diseases 
underlies either defects or excesses of apoptosis and that 
Bcl-2 deregulation plays a key role in apoptosis execution. 
On this basis, Bcl-2 still represent a preferred target for 
innovative cancer therapies [40-42] and some clinical trials 
have also been recently described [43]. For more than two 
decades, we have used the antisense strategy as potential 
therapeutic tool, and (besides the Bcl-2/IgH AS in t(14;18) 
cells), we have chosen the Bcl-2 ARE as rationally preferred 
oligonucleotide target to down or up regulate Bcl-2 
expression. Indeed, the simulated folding of Bcl-2 ARE by 
the MUFOLD program [44] indicates that it forms a relatively 
wide loop and is therefore an optimal target both for natural 
endogenous molecules (the Bcl-2 AUBPs) and for synthetic 
exogenous molecules (such as, antisense oligonucleotides 
and ribozymes). 
To downregulate Bcl-2 expression in apoptosis-defective 
Bcl-2 overexpressing Raji cells, we targeted the Bcl-2 ARE 
with a synthetic hammerhead ribozyme [45], designed relying 
on in vitro results obtained by probing RNA accessibility to 
antisense ODNs. The cellular uptake of this lipotransfected 
ribozyme resulted in a marked reduction of Bcl-2 mRNA and 
Bcl-2 protein levels and a dramatic increase of cell death by 
apoptosis. Although the Bcl-2 ARE is not a tumour specific 
target, we proposed to evaluate such ribozyme as potential 
therapeutic tool for the treatment of Bcl-2 overexpressing 
tumors. 
Symmetrically, we have attempted to prevent Bcl-2 
dowregulation, thereby inhibiting apoptosis in pathological 
conditions characterized by apoptosis excesses, by targeting 
the Bcl-2 ARE with three 26-mer 2’-O-methyl 
oligoribonucleotides (ORNs) homologous to the core region 
of the Bcl-2 ARE used as decoy-aptamers. Sense-oriented 
ORNs competed with the Bcl-2 ARE for the interaction with 
both destabilizing and stabilizing AUBPs in cell-free systems 
and in cell lines [26]. Moreover, ORNs induced mRNA 
stabilization and therefore up regulated both Bcl-2 mRNA 
and protein levels. Furthermore, Bcl-2 ORNs stabilized other 
ARE containing transcripts and up regulated their expression. 
We also demonstrated that treatment of the SHSY-5Y 
neuronal cells with Bcl-2 ORNs prevented Bcl-2 
down-regulation in response to apoptotic stimuli, such as 
glucose/growth factor starvation or oxygen deprivation, 
inhibited cell cycle entry and induced a markedly increase of 
cellular neurite number and length, a hallmark of neuronal 
differentiation resulting from Bcl-2 up-regulation [46]. 
Enhancement of apoptotic threshold and induction neuronal 
differentiation by Bcl-2 ORNs suggested evaluating their 
potential application to prevent pathological apoptosis and 
neuronal degenerations. 
The previously described results confirmed that the 
destabilizing activity of Bcl-2 mRNA ARE, we discovered 
thanks to the Bcl-2/IgH AS, underlies a new mechanism of 
post-transcriptional control of Bcl-2 expression, whose 
disruption could contribute to the oncogenicity of this 
antiapoptotic gene. Furthermore, they demonstrated that the 
Bcl-2 ARE represents an optimal target for antisense 
strategies aimed to down- or up-regulate Bcl-2 expression, 
thereby modulating apoptosis in apoptosis 
deregulation-related diseases. 
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